FMP
Charles River Laboratories International, Inc.
CRL
NYSE
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
171.04 USD
4.11 (2.4%)
Mr. James C. Foster J.D.
Healthcare
Medical - Diagnostics & Research
NYSE
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
0001100682
US1598641074
159864107
251 Ballardvale Street
781 222 6000
US
18,700
Jun 23, 2000
Mr. James C. Foster J.D.
Chairman, President & Chief Executive Of...
2.66M
1951
Ms. Flavia H. Pease
Corporate Executive Vice President & Chi...
1.66M
1974
Mr. Mark Mintz
Corporate Senior Vice President & Chief ...
0
N/A
Mr. Todd Spencer
Corporate Vice President of Investor Rel...
0
N/A
Mr. Joseph W. LaPlume J.D.
Corporate Executive Vice President of Co...
928.36k
1974
Mr. Michael Gunnar Knell
Corporate Senior Vice President & Chief ...
0
1977
Ms. Amy Cianciaruso
Corporate Vice President & Chief Communi...
0
N/A
Prof. Julie Frearson Ph.D.
Corporate Senior Vice President & Chief ...
0
N/A
Ms. Birgit Girshick
Corporate Executive Vice President & Chi...
1.28M
1970
Mr. Matthew L. Daniel J.D.
Corporate Senior Vice President, General...
0
N/A
As of December 31, 2024, the total employee count stands at 18,700, with compensation values reflecting the last fiscal year ending on that date. Pay encompasses salary, bonuses, etc., All figures are in USD.